SAB Biotherapeutics, Inc. Cash Flow Statement

Cash Flow Statement Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Operating Activities
Net Income 20.11M-17.14M-18.74M-42.19M-41.94M
Share-based Compensation 1.30M2.31M2.67M3.88M2.94M
Deferred Taxes -0.10M0.10M-1.32M
Gains from Sales and Divestitures 0.01M0.02M
Gains from Investment Securities 4.10M5.11M0.71M1.01M2.97M
Non-cash Items 28.90M0.11M0.66M6.30M
Change in Interest Receivables 0.05M
Cash from Operations 10.00M1.99M-23.46M-25.12M-34.29M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles 0.17M0.16M0.12M0.10M0.24M
Amortization of Deferred Charges 0.17M0.16M
Depreciation & Amortization (CF) 0.38M1.49M3.20M3.70M4.71M
Change in Working Capital
Change in Receivables 17.75M-12.56M-2.45M-5.56M
Change in Account Payables 5.21M-2.94M-0.78M-2.70M0.92M
Change in Accured Expenses 1.41M3.38M-2.54M-1.71M-1.23M
Investing Activities
Capital Expenditures 12.73M10.94M2.17M0.20M0.34M
Sales of Property, Plant and Equipment 0.01M0.08M0.04M
Divestments 34.34M
Change in Acquisitions & Divestments 25.82M
Cash from Investing Activities -12.72M-10.94M-2.09M-0.15M-11.96M
Financing Activities
Other financing activities 1.30M0.01M0.08M0.01M0.02M
Debt Issuance and Repayment
Long-Term Debt Issuances 2.84M1.24M0.77M0.52M
Long-Term Debt Repayments 0.03M1.09M2.26M1.03M1.29M
Change in Capital Stock
Shares Issued 9.90M0.01M7.68M59.65M0.02M
Preferred Shares Issued 7.50M
Misc.
Cash from Financing Activities 8.98M35.89M1.05M66.77M-1.17M
Exchange Rate Effect 0.02M-0.24M
Change in Cash 6.26M26.93M-24.50M41.52M-47.67M
Beginning Cash Balance 1.36M5.52M
Free Cash Flow -2.73M-8.96M-25.63M-25.32M-34.63M
Net Cash Flow 6.26M26.93M-24.50M41.50M-47.43M